![BUTTS STEVE](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
BUTTS STEVE
Vorstandsvorsitzender bei Arrivo Management LLC
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Stephen E. Butts | M | - |
Aerial BioPharma LLC
![]() Aerial BioPharma LLC Pharmaceuticals: MajorHealth Technology Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC.
Arrivo Management LLC
![]() Arrivo Management LLC BiotechnologyHealth Technology Arrivo Management LLC is a biopharmaceutical company. It develops biologics and small molecules to improve patient lives. The company was founded by Steve Butts, Bill Wofford, Michael Ackermann and Jed Black on July 9, 2015 and is headquartered in Morrisville, NC.
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 13 Jahre |
C. Adair | M | - |
Arrivo Management LLC
![]() Arrivo Management LLC BiotechnologyHealth Technology Arrivo Management LLC is a biopharmaceutical company. It develops biologics and small molecules to improve patient lives. The company was founded by Steve Butts, Bill Wofford, Michael Ackermann and Jed Black on July 9, 2015 and is headquartered in Morrisville, NC.
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.
Aerial BioPharma LLC
![]() Aerial BioPharma LLC Pharmaceuticals: MajorHealth Technology Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC.
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 12 Jahre |
Michael E. Bozik | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Michael Ackermann | M | - |
Arrivo Management LLC
![]() Arrivo Management LLC BiotechnologyHealth Technology Arrivo Management LLC is a biopharmaceutical company. It develops biologics and small molecules to improve patient lives. The company was founded by Steve Butts, Bill Wofford, Michael Ackermann and Jed Black on July 9, 2015 and is headquartered in Morrisville, NC.
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 9 Jahre |
Moise Khayrallah | M | - |
Aerial BioPharma LLC
![]() Aerial BioPharma LLC Pharmaceuticals: MajorHealth Technology Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC.
QuatroBio LLC
![]() QuatroBio LLC Miscellaneous Commercial ServicesCommercial Services QuatroBio LLC engages in drug development services. The company was founded by Moise A. Khayrallah on September 4, 2014 and is headquartered in Morrisville, NC. | 13 Jahre |
Gregory T. Hebrank | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 20 Jahre |
Jorge Bartolome | M | - |
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
G. Steve Arnold | M | - |
EnviCor Enterprises LLC
![]() EnviCor Enterprises LLC Industrial MachineryProducer Manufacturing EnviCor Enterprises LLC designs and manufactures plastic molders. It offers custom molders for the manufacture of paddle boards, barrels, plastic containers, septic equipment and water tanks. The company was founded by G. Steve Arnold in 2006 and is headquartered in Smithfield, NC. | 18 Jahre |
Thomas Petzinger | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 20 Jahre |
William N. Wofford | M | - |
Arrivo Management LLC
![]() Arrivo Management LLC BiotechnologyHealth Technology Arrivo Management LLC is a biopharmaceutical company. It develops biologics and small molecules to improve patient lives. The company was founded by Steve Butts, Bill Wofford, Michael Ackermann and Jed Black on July 9, 2015 and is headquartered in Morrisville, NC. | 9 Jahre |
Gary Bream | M | - |
Aerial BioPharma LLC
![]() Aerial BioPharma LLC Pharmaceuticals: MajorHealth Technology Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC. | 13 Jahre |
Benjamin Gomez | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Mark Hackett | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 9 Jahre |
Ian Read | M | 71 |
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Elyse Stock | M | 66 |
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
BULLOCK JIM | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | - |
Baker Keith | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | - |
KENNEDY LIZBETH | F | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 9 Jahre |
Dooley Robert | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | - |
TRAVIS MANASCO | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 2 Jahre |
Rader Scott | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 4 Jahre |
Amy Grogg | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 2 Jahre |
Frank Butler | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 4 Jahre |
JOSHUA ECKELBERRY | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 6 Jahre |
Rachel Kopper | F | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
Michael Hoey | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 7 Jahre |
Gail Page | M | 68 |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | - |
David A. Belitz | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | - |
Paul Berns | M | 57 |
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Adam Koppel | M | 54 |
Areteia Therapeutics, Inc.
![]() Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Casey Hammontree | M | - |
Solas Bioventures (mayfield) LLC
![]() Solas Bioventures (mayfield) LLC Investment ManagersFinance Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee. | 10 Jahre |
James W. Dean | M | 53 |
Kenan-Flagler Business School
| 26 Jahre |
Steven Dworetzky | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 17 Jahre |
Donald G. Archibald | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 16 Jahre |
David P. Ward | M | - |
Aerial BioPharma LLC
![]() Aerial BioPharma LLC Pharmaceuticals: MajorHealth Technology Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC. | 13 Jahre |
Jeff McCormick | M | - |
Knopp Biosciences LLC
![]() Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 18 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Byron Hewett | M | 66 |
BioBehavioral Diagnostics Co.
![]() BioBehavioral Diagnostics Co. Medical SpecialtiesHealth Technology BioBehavioral Diagnostics Co. manufactures and markets attention-deficit hyperactivity disorder systems. It develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The firm's product Quotient ADHD System measures impulsivity, hyperactivity and inattention as an aid in the assessment of ADHD and this system includes a data acquisition unit, a proprietary normative database, analytics and reports. The company was founded by Eric B. Gordon in 2006 and is headquartered in Westford, MA. | - |
Carrie Mulherin | F | - |
BioBehavioral Diagnostics Co.
![]() BioBehavioral Diagnostics Co. Medical SpecialtiesHealth Technology BioBehavioral Diagnostics Co. manufactures and markets attention-deficit hyperactivity disorder systems. It develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The firm's product Quotient ADHD System measures impulsivity, hyperactivity and inattention as an aid in the assessment of ADHD and this system includes a data acquisition unit, a proprietary normative database, analytics and reports. The company was founded by Eric B. Gordon in 2006 and is headquartered in Westford, MA. | - |
Jim Jeffries | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Todd Foust | M | - |
Kenan-Flagler Business School
| 1 Jahre |
Chris Bennett | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Matt Levenson | M | - |
Kenan-Flagler Business School
| 4 Jahre |
Bradford Whitehurst | M | 49 |
Kenan-Flagler Business School
| 1 Jahre |
Michel Brousset | M | 51 |
Kenan-Flagler Business School
| 2 Jahre |
Kenneth S. Freeman | M | - |
Aerial BioPharma LLC
![]() Aerial BioPharma LLC Pharmaceuticals: MajorHealth Technology Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC. | 2 Jahre |
Patrick Markey | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Michael E. Block | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Susan Cates | F | 53 |
Kenan-Flagler Business School
| 2 Jahre |
Greg Buckley | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Jorn Gorlach | M | 62 |
Kenan-Flagler Business School
| 2 Jahre |
Erik Reese | M | - |
BioBehavioral Diagnostics Co.
![]() BioBehavioral Diagnostics Co. Medical SpecialtiesHealth Technology BioBehavioral Diagnostics Co. manufactures and markets attention-deficit hyperactivity disorder systems. It develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The firm's product Quotient ADHD System measures impulsivity, hyperactivity and inattention as an aid in the assessment of ADHD and this system includes a data acquisition unit, a proprietary normative database, analytics and reports. The company was founded by Eric B. Gordon in 2006 and is headquartered in Westford, MA. | - |
Andrew Fentress | M | 54 |
Kenan-Flagler Business School
| 2 Jahre |
Chris Konstantinos | M | - |
Kenan-Flagler Business School
| 4 Jahre |
Teresa O. Lipcsey | F | - |
BioBehavioral Diagnostics Co.
![]() BioBehavioral Diagnostics Co. Medical SpecialtiesHealth Technology BioBehavioral Diagnostics Co. manufactures and markets attention-deficit hyperactivity disorder systems. It develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The firm's product Quotient ADHD System measures impulsivity, hyperactivity and inattention as an aid in the assessment of ADHD and this system includes a data acquisition unit, a proprietary normative database, analytics and reports. The company was founded by Eric B. Gordon in 2006 and is headquartered in Westford, MA. | - |
Bonny Moellenbrock | F | - |
Kenan-Flagler Business School
| 2 Jahre |
Andrew Boisseau | M | - |
Kenan-Flagler Business School
| 4 Jahre |
Lee Brading | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Sandy Smith | M | 77 |
BioBehavioral Diagnostics Co.
![]() BioBehavioral Diagnostics Co. Medical SpecialtiesHealth Technology BioBehavioral Diagnostics Co. manufactures and markets attention-deficit hyperactivity disorder systems. It develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The firm's product Quotient ADHD System measures impulsivity, hyperactivity and inattention as an aid in the assessment of ADHD and this system includes a data acquisition unit, a proprietary normative database, analytics and reports. The company was founded by Eric B. Gordon in 2006 and is headquartered in Westford, MA. | - |
Ian Howes | M | 66 |
Kenan-Flagler Business School
| 2 Jahre |
Robert Sullivan | M | 80 |
Kenan-Flagler Business School
| 5 Jahre |
Sean Ivery | M | - |
Kenan-Flagler Business School
| 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 61 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- BUTTS STEVE
- Persönliches Netzwerk